文献速递肝病消化道肿瘤与早癌

HBeAg阳性期持续高HBsAg水平预测慢性乙型肝炎患者肝癌风险较低

Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients.
PubMed 文献 · Aliment Pharmacol Ther · 2024-02-27

基于REVEAL-HBV队列中319例HBeAg阳性慢性乙型肝炎患者,中位随访11年识别HBsAg轨迹。持续高HBsAg组(≥104 IU/mL)肝癌年发病率为0.37%,低于非稳定组的1.16%(p=0.03)。非稳定组、年龄>40岁和基因型C是肝癌独立预测因素。

要点

  • HBeAg阳性期持续高HBsAg(≥104 IU/mL)者肝癌风险较低。
  • 非稳定HBsAg轨迹者肝癌风险是持续高组的3.50倍。
  • 持续高HBsAg组中仅 basal core promoter 突变与肝癌风险相关。

核心结论

  • HBeAg血清阳性期持续高HBsAg水平代表肝癌低风险的特殊人群。

研究设计与样本

  • REVEAL-HBV队列中HBeAg阳性且HBeAg清除前至少2次HBsAg检测的319例患者,中位HBeAg阳性期11年,采用基于组的轨迹模型和Cox回归分析。

主要发现

  • 持续高组(n=72)HBsAg持续≥104 IU/mL,非稳定组(n=233)基线低或随访中降至<104 IU/mL。
  • 非稳定组ALT异常、HBV基因型C和 basal core 突变比例高于持续高组(p<0.05)。
  • 持续高组和非稳定组肝癌年发病率分别为0.37%和1.16%(p=0.03)。
  • 多因素分析中年龄>40岁(HRadj=4.11,95%CI 2.26-7.48)、基因型C(HRadj=4.39,95%CI 1.96-9.81)和非稳定组(HRadj=3.50,95%CI 1.49-8.21)为肝癌独立预测因素。
  • 持续高HBsAg组中仅 basal core promoter 突变与肝癌风险相关(HRadj=32.75,95%CI 5.41-198.42)。

临床怎么用

  • 对于HBeAg阳性慢性乙型肝炎患者,可依据HBsAg轨迹识别肝癌低风险人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High hepatitis B surface antigen (HBsAg) level predicts hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients with low viral load. The role of longitudinal HBsAg levels in predicting HCC in HBeAg-positive CHB patients remains unknown. METHOD: HBeAg-positive CHB participants from the REVEAL-HBV cohort with ≥2 HBsAg measurements before HBeAg seroclearance were enrolled. Group-based trajectory modelling identified distinct HBsAg trajectory groups during a median of 11 years of HBeAg-positive status. Cox regression models were applied for investigating independent predictors of HCC and estimating adjusted hazard ratio (HRadj) with a 95% confidence interval (CI). A p-value less than 0.05 was considered statistically significant. RESULTS: A total of 319 patients were enrolled and classified by HBsAg trajectory patterns as (A) persistently high group (n = 72): HBsAg persistently ≥104 IU/mL, and (B) non-stationary group (n = 233): low HBsAg at baseline or declining to <104 IU/mL during the follow-up. Group B had higher proportions of abnormal ALT levels, HBV genotype C and basal core mutation than group A (p < 0.05); age at entry and gender were comparable. The annual incidence of HCC in group A and group B were 0.37% and 1.16%, respectively (p = 0.03). In multivariate analysis, age >40 years (HRadj [95% CI] = 4.11 [2.26-7.48]), genotype C (HRadj [95% CI] = 4.39 [1.96-9.81]) and the non-stationary group (HRadj [95% CI] = 3.50 [1.49-8.21]) were independent predictors of HCC. Basal core promoter mutation was the only risk factor of HCC in the persistently high HBsAg group (HRadj [95% CI] = 32.75 [5.41-198.42]). CONCLUSION: Patients with persistently high HBsAg levels during HBeAg-seropositive stage represent a unique population with low risk of HCC development.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Lin HC, Jeng WJ, Liu J, et al. Persistently high HBsAg levels during HBeAg-seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients. Aliment Pharmacol Ther. 2024. PMID: 38410882. doi:10.1111/apt.17915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。